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Tel: 020 7035 0454  
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Rt Hon Alan Johnson MP 
2 Marsham Street 
London  
SW1P 4DF 
16th July 2009 
 
Dear Home Secretary,  
 
I outlined in my letter of 8th April 2009 that I would write to your predecessor 
with advice regarding the synthetic cannabinoid receptor agonists (hereafter 
termed ‘synthetic cannabinoids’) which includes the smoking mixture ‘Spice’. 
The ACMD has now considered the issue further and I am pleased to present 
to you our advice in the attached report.  
 
Forensic analysis of herbal material purported to have psychotropic effects 
recently revealed the presence of synthetic cannabinoids. It would appear that 
these synthetic compounds had been sprayed onto a plant based mix (that 
does not contain tobacco or cannabis) for the purposes of achieving 
intoxication from smoking. Samples analysed in UK, German and other 
laboratories have been found to contain synthetic cannabinoids that are 
believed to be of a higher potency than tetrahydrocannabinol (THC): the 
active principle in cannabis. We have received reports that such mixes are 
commonly available for purchase over the internet and also in ‘head-shops’. 
The ACMD has been made aware of the brand ‘Spice’ under which some 
material is marketed.  
 
Our report explains that the detailed pharmacology of these synthetic 
compounds is, as yet, unknown. There are also a large number of potential 
cannabinoids that could be synthesised. However, some inferences can be 
made based on the chemistry of the drugs identified to date and it is very 
likely that these synthetic cannabinoids will produce harmful effects similar to 
those associated with THC. Indeed, our report notes that the substances 
containing the synthetic cannabinoids have the potential to be more harmful 
than cannabis due to their method of manufacture and that the compounds 
present and their quantity (and hence potency) is unknown to the user.  
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After consideration of the available evidence, the ACMD concludes that with 
respect to the classification of substances under the Misuse of Drugs Act, the 
harms of the synthetic cannabinoids are broadly commensurate with those of 
cannabis and that they should be classified accordingly.  
 
The ACMD also recommends that, with named exemptions, the synthetic 
cannabinoids are placed in Schedule 1 of the Misuse of Drugs Regulations 
(1975 – and as subsequently amended) on the grounds they have no 
recognised medicinal use. We recommend that nabilone, as a component of 
an existing medicinal product (Cesamet) should be placed in Schedule 2 of 
the Misuse of Drugs Regulations (2001).   
 
The report also notes that the ACMD has carefully considered advising 
generic legislation to control these substances under the Misuse of Drugs Act 
1971. Presently, only a small number of synthetic cannabinoids have been 
identified in ‘Spice’. However, the potential range of substances presents 
some challenges to ensure that any legislative changes are not easily 
subverted by manufacturers changing the compounds they add to the plant-
based mix. This concern is supported by recent experience in Germany that 
suggests that should one of the cannabinoids be controlled, manufacturers 
move to adding a chemically different, yet functionally similar, synthetic 
cannabinoid in the ‘Spice’ mix. Due to the number of variations, it is highly 
likely that specific legislation would always run some way behind the 
availability of a legal mix on the street. The ACMD therefore proposes generic 
legislation to control the synthetic cannabinoids that are, or could in the future, 
be used in preparations, without impacting on any legitimate use of these or 
related substances. Five substances are proposed for control by name. 
 
I would welcome the opportunity to meet with you should you want to discuss 
these matters.  
 
Yours faithfully, 
 
 
 
 
 
 
Professor David Nutt FMed Sci 
 
 
ACMD report on the major cannabinoid agonists 
 4
1. Background 
In March 2009 the former Home Secretary requested advice on legal highs 
and ‘Spice’ in particular. The ACMD wrote to the Home Secretary (Annex B) 
setting out the ACMD’s current thinking on Spice. The ACMD considered the 
synthetic cannabinoids at a Technical meeting (10th March 2009) and at 
Council meetings on the 24th March 2009 and 14th May 2009.   
 
This report draws on much of the evidence cited in the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) recent assessment1 of 
synthetic cannabinoids, based on an expert meeting held in Lisbon on 6th 
March 2009.   
 
 
 
 
 
                                                 
1 http://www.emcdda.europa.eu/drug-situation/new-drugs 
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2. Introduction 
For the purposes of this report we term the synthetic cannabinoid agonists as 
‘synthetic cannabinoids’. In the strictest chemical-structure sense many of the 
substances named in this report are not cannabinoids, nevertheless the term 
is widely used to refer to these chemically unrelated structures as they are 
cannabinoid-like in their activity.   
 
The synthetic cannabinoids considered in this report are CB1 receptor 
agonists. The CB1 receptor in the brain mediates the psychoactive effects of 
tetrahydrocannabinol (THC), the active principle in cannabis. The synthetic 
cannabinoids thus mimic the effects of THC. Developed by the 
pharmaceutical industry and academic laboratories over the past 40 years, 
they were investigated as potential pharmaceutical agents, often for the 
treatment of pain, but it proved impossible to separate the desired activity 
from unwanted psychoactive effects.  
 
Forensic analysis of a number of herbal materials recently revealed the 
presence of synthetic cannabinoids. It would appear that these synthetic 
compounds had been sprayed onto a plant-based mix (that does not contain 
tobacco or cannabis) for the purposes of achieving intoxication from smoking. 
The plant-based mixes are commonly available over the internet and also in 
‘head-shops’.  
 
‘Spice’ is an example of a brand name for a mixture of herbs that are sold in 
‘head shops’ in Europe, Canada and New Zealand as an incense or room 
odouriser, as well as through Internet sites as an herbal smoking blend.  The 
substance is usually smoked in the belief that it will deliver ‘cannabis-like 
effects’. The drug is also known as ‘Spice Silver’, ‘Spice Gold’, ‘Spice 
Diamond’, ‘Spice Arctic Synergy’ and ‘Spice Yukatan Fire’. Spice Gold can be 
brought for £20 (3g) through Internet sites.  
 
Herbs that are listed on the packaging include; Canavalia maritima, 
Nymphaea caerulea, Scutellaria nana, Pedicularis densiflora, Leonotis 
leonurus, Zornia latifolia, Nelumbo nucifera and Leonurus sibiricus. However, 
following analyses by German Laboratories it was found that many of the 
listed ingredients were not present.  Instead, large amounts of synthetic 
tocopherol (Vitamin E) were present, possibly intended to mask the analytical 
detection of the active cannabinoids.   
 
3. Structural classification  
The synthetic cannabinoid receptor agonists fall into seven major groups2:  
(1) naphthoylindoles; 
(2) naphthylmethylindoles;  
(3) naphthoylpyrroles;  
(4) naphthylmethylindenes;  
(5) phenylacetylindoles (i.e. benzoylindoles);  
(6) cyclohexylphenols;  
(7) classical cannabinoids (dibenzopyrans);  
                                                 
2 See tables 1-7, Annex A 
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Compounds in Groups (1-5) were largely synthesised by Huffman et al., (JWH 
compounds) at Clemson University, USA, during the past 15 years. The 
cyclohexylphenols (CP compounds) were developed by Pfizer during the 
1970’s and 1980’s, whereas the synthesis of the classical cannabinoids 
began in the 1960’s following the elucidation of the chemical structure of THC.  
 
The only cannabinoids to be licensed as medicines in the UK, albeit with 
restricted use, are THC (dronabinol) and nabilone; their structures are 
included in table 7 below for comparison. Although other miscellaneous 
synthetic cannabinoids are known (see e.g. Refs 4 and 9), they are either 
weak agonists at the CB1 receptor or are receptor antagonists or mixed 
agonists/antagonists, hence they have little if any psychotropic actions and so 
are not considered here. A further complication with some cannabinoids is 
that they may show physiological effects unrelated to cannabinoid receptors. 
 
The tables (1-7) in Annex A show the structural skeleton of each group, the 
substitution pattern and mean affinity constants (Ki) for the CB1 receptor. High 
affinity is defined here as Ki < 100nM. It is unlikely that low-affinity agonists (Ki 
> 100nM) would prove attractive to illicit users. For example, THC (Ki  = 
10.2nM) is approximately ten times more potent than a substance with Ki = 
100nM.   
 
There are a number of gaps in the numerical sequence of the JWH 
compounds, but many of the ‘missing’ structures are selective agonists or 
antagonists of the CB2 cannabinoid receptor and have limited potential for 
misuse. 
 
4. Prevalence 
The EMCDDA has conducted a short survey of European Union Member 
States to collect basic information on the availability of products containing 
synthetic cannabinoids. The questionnaire that was sent contained questions 
on ‘Spice’ products and JWH-018, but did not include other specific 
compounds (e.g. CP 47,497) as these have only subsequently been reported. 
The returns found that ‘Spice’ products were identified in 21 of the 30 
participating countries (EMCDDA, 2009). In this survey ‘identification’ was 
defined as available – not necessarily requiring forensic analysis. However, 
Spice products and/or JWH-018 have been positively identified by 
toxicological or forensic analysis in 8 out of those 21 countries where such 
products were available.  
 
However, data on prevalence are limited as in most member states, as in the 
UK, these substances are not controlled and are therefore unlikely to be 
submitted for forensic analysis. Because they represent a very recent 
phenomenon, there have been no published population, household or user 
surveys. 
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Recent forensic analysis (June 2009) of test purchased UK samples from UK 
websites of ‘Spice-like’ products has shown the presence of JWH-018, CP 
47,497 and HU-2103. 
 
To a large extent, ‘Spice’ and related products are sold via Internet sites 
located in the UK and many other countries. Sales are also made via ‘head 
shops’. The size of this market is unknown but we are aware it is extensive 
and the networks of distribution are well developed.  
 
5. Physical and Social harms 
Evidence concerning the harms of these synthetic cannabinoids is not well 
understood nor well published because of their recent appearance on the 
market. However the EMCDDA recently published a briefing paper that sets 
out the key issues and identifies potential harms4.  
 
The EMCDDA note in their report (2009) that a number of in vitro and animal 
studies have been published (including derivation of structure activity 
relationships). However, there are no pharmaceutical products that have 
emerged nor are there human studies on these compounds (EMCDDA, 
2009).  
 
Physical and mental harms 
The specific risks users take with the synthetic cannabinoids are, in part, 
unknown as neither their metabolism nor their toxicology has been extensively 
studied. Considering the harms of the synthetic cannabinoids analogous to 
those of THC may underestimate their potential harms.  
 
Because substances that contain the synthetic cannabinoids are 
manufactured, there can be considerable inter-and intra-batch variability, both 
in terms of substances present and quantity. Users cannot therefore assume 
the same effects from the same product the next time they use it. Thus, there 
is potential for overdose should a person use a particularly strong batch or a 
synthetic cannabinoid with particularly high potency. What the clinical 
outcomes of such an overdose would be can, at present, only be speculated, 
but are likely to include significant alterations in mental state with paranoia 
and perceptual disruptions such as are produced by high THC exposure.  
 
Pigee (2009) refers to media reports from Germany where a number of users 
of ‘herbal incense’ presented to emergency rooms with psychosis-like panic 
attacks and heart and circulatory problems (also see Auwarter, 2009). 
 
The EMCDDA report (2009) suggests that tolerance to these synthetic 
cannabinoids may develop fairly fast. There are therefore concerns that users 
may be at a greater risk of developing dependence. Evidence of a withdrawal 
effect after smoking ‘Spice Gold’ has been reported by Zimmermann et al. 
(2009).
                                                 
3 http://www.ltg.uk.net/admin/files/Spice.pdf 
4http://www.emcdda.europa.eu/drug-situation/new-drugs 
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Societal harms 
As there are no estimates of the number of users of Spice, either in the UK or 
other EU countries it is difficult to estimate the current societal harms. 
However, it is plausible to expect that the societal harms have the potential to 
be comparable to those of cannabis. 
 
6. Options for control 
Specific control of substances offers the simplest approach, but not only 
would this require the listing of a large number of compounds by their 
systematic names, there is a risk that any such list would not be exhaustive. 
In other words, non-controlled (designer) analogues could rapidly appear on 
the illicit market. 
 
Generic control is appropriate for groups of substances where: 
 
• Relatively simple substitution patterns occur in a structural nucleus 
• A large number of examples are already known 
• Synthesis of further analogues might be anticipated 
• The target group can be encompassed with a simple definition. 
 
6.1. Generic control 
The following generic definitions for the major groups of cannabinoids are 
proposed. For Groups 1- 6, N refers to the number of examples shown in the 
tables in Annex A. 
 
Table 1 and 2: Groups 1 and 2 (Naphthoylindoles and naphthylmethylindoles) 
(N = 74 and 9 respectively) 
 
“Any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-
yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring 
by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl 
whether or not further substituted in the indole ring to any extent , whether or 
not substituted in the naphthyl ring to any extent.” 
 
Table 3: Group 3 (Naphthoylpyrroles) 
(N = 32) 
 
“Any compound structurally derived from 3-(1-naphthoyl)pyrrole by 
substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, 
cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not 
further substituted in the pyrrole ring to any extent ,whether or not substituted 
in the naphthyl ring to any extent..” 
 
Table 4: Group 4 (Naphthylmethylindenes) 
(N = 3) 
 
“Any compound structurally derived from 1-(1-naphthylmethyl)indene by 
substitution at the 3-position of the indene ring by alkyl, alkenyl, 
cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl whether or not 
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further substituted in the indene ring to any extent, whether or not substituted 
in the naphthyl ring to any extent.” 
 
Table 5: Group 5 (Phenylacetylindoles) 
(N = 28) 
“Any compound structurally derived from 3-phenylacetylindole by substitution 
at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, 
cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in 
the indole ring to any extent, whether or not substituted in the phenyl ring to 
any extent.” 
 
Table 6: Group 6 (Cyclohexylphenols) 
(N = 16) 
 
“Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by 
substitution at the 5-position of the phenolic ring by alkyl, alkenyl, 
cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not 
substituted in the cyclohexyl ring to any extent .” 
 
6.2. Specific control 
In Part IV of Schedule 2 of the Misuse of Drugs Act, cannabinol derivatives 
are defined as: 
 
“…the following substances, except where contained in cannabis or cannabis 
resin, namely tetrahydro derivatives of cannabinol and 3-alkyl homologues of 
cannabinol or of its tetrahydro derivatives”.  
 
This definition captures several cannabinol derivatives as shown in Annex A, 
table 7 (Group 7), some of which are among the most potent cannabinoids 
known (Ref 10).  
 
Further substances, as shown below, are commercially available, and are 
used as research tools. They are potentially misusable, but are not captured 
by the existing or proposed definitions. In each case, it is suggested that they 
should be named specifically. 
 
6.2.1  
HU-2105 is a classical cannabinoid closely related to THC. The overarching 
control of stereoisomers in the Misuse of Drugs Act would normally apply 
automatically to all of the cannabinoid groups considered here if they became 
controlled drugs. However, the 6aR,10aR enantiomer of HU210 (known as 
HU-211 or dexanabinol; Ref 4) is a non-psychotropic cannabinoid with 
antagonist actions at the NMDA glutamate receptor. It has some potential as 
a neuroprotective agent and could be made exempt, as required, by license. 
 
                                                 
5 9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrob 
enzo[c]chromen-1-ol 
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6.2.2.  
Nabilone6 is also chemically related to THC. It is a component of an existing 
medicinal product (Cesamet), but is not widely used.  
 
6.2.3  
WIN-55,212-27 is closely related to the naphthoylindoles in Group 1. 
 
6.2.4  
HU-2438 is chemically related to THC. 
 
6.2.5  
CP 50,55619, one stereoisomer of which is known as levonantradol, is closely 
related to the substances shown in Group 6. 
 
6.2.6 
[This paragraph has been withheld on the ground that its publication would 
not be in the public interest.]   
 
7.  
[This paragraph has been withheld on the ground that its publication would 
not be in the public interest.]   
 
                                                 
6 1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-7,8,10,10a-tetrahydro-6H-benzo 
[c]chromen-9(6aH)-one 
7 [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de)-1,4-benzoxazin-6-yl]- 
1-napthalenylmethanone 
8 3-dimethylheptyl-11-hydroxyhexahydrocannabinol 
9 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-
1-yl]acetate 
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8. Conclusions/Recommendations 
 
Recommendation 1 
The ACMD recommend that the substances detailed in Annex A, herein 
termed synthetic cannabinoids, have potential harms commensurate with 
those of cannabis and should be classified and controlled under the Misuse of 
Drugs Act (1971) accordingly.  
 
Recommendation 2 
The ACMD also recommends that, with named exemptions, the above 
synthetic cannabinoids are placed in Schedule 1 of the Misuse of Drugs 
Regulations (2001) on the grounds they have no recognised medicinal use. 
We recommend that nabilone, as a component of an existing medicinal 
product (Cesamet) should be placed in Schedule 2 of the Misuse of Drugs 
Regulations (2001).   
 
Recommendation 3 
To achieve the required legislation the ACMD recommends that the majority 
of substances be brought under control by means of generic definitions. 
However, 5 substances are recommended as being named for specific 
control: HU-210, nabilone, WIN-55,212-2, HU-243 and CP 50,5561. 
 
Recommendation 4 
[This recommendation has been withheld on the ground that its publication 
would not be in the public interest.]   
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Annex A.  
In the following tables (1-7), the affinity constants (Ki) of the cannabinoid 
agonists, where known, are listed. The lower the value of Ki, the higher is the 
expected potency. Although determined in vitro, there is evidence that these 
constants correlate with pharmacological effects in animals (Vann et al., 2009) 
Furthermore, like the naturally-occurring THC, those synthetic cannabinoids 
reported in ‘Spice’ and related products have low Ki values. In the tables, 
substances with high Ki, values (shown as ‘Low affinity for the CB1 receptor’) 
are unlikely to be misused. 
 
Small discrepancies exist in Ki values for similar substances between different 
publications. Some structures exhibit geometrical isomerism, where the 
separate isomers may show different receptor activity, but a distinction is not 
always made in the published literature. In the following tables, the 
abbreviation MPE refers to a 2-(4-morpholino)ethyl substituent. 
 
Substances which have been reported in smoking mixtures are shown 
emboldened/highlighted. The tables also indicate which substances are 
currently controlled in Germany (D), Austria (A) and France (F).
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Table 1. Group 1: Naphthoylindoles
N
O
R1
R2
R3
R4
 
 
Substance R1 R2 R3 R4 Comments Ki (nM) 
JWH-004 Hexyl Methyl H H Ref 8 48 
JWH-007 Pentyl Methyl H H Ref 1 2.9 
JWH-009 Heptyl Methyl H H Ref 8 Low affinity for CB1 receptor >1000 
JWH-015 Propyl Methyl H H Ref 2, Ref 6 Low affinity for CB1 receptor 165 
JWH-016 Butyl Methyl H H Ref 8 22 
JWH-018 Pentyl H H H Ref 1 Controlled in D, A and F. 2.9 
JWH-019 Hexyl H H H Ref 5 9.8 
JWH-020 Heptyl H H H Ref 5  Low affinity for CB1 receptor 128 
JWH-046 Propyl Methyl H Methyl Ref 6  Low affinity for CB1 receptor 343 
JWH-047 Butyl Methyl H Methyl Ref 8 59 
JWH-048 Pentyl Methyl H Methyl Ref 6 10.7 
JWH-049 Hexyl Methyl H Methyl Ref 8 55 
JWH-050 Heptyl Methyl H Methyl Ref 8 342 
JWH-070 Methyl H H H Ref 5   Low affinity for CB1 receptor >1000 
JWH-071 Ethyl H H H Ref 5   Low affinity for CB1 receptor >1000 
JWH-072 Propyl H H H Ref 5   Low affinity for CB1 receptor >1000 
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Group 1: Naphthoylindoles – contd. 
 
Substance R1 R2 R3 R4 Comments Ki (nM) 
JWH-073 Butyl H H H Ref 2 (not shown in cited literature) 8.9 
JWH-076 Propyl H H Methyl Ref 6  Low affinity for CB1 receptor 214 
JWH-079 Propyl H Methoxy H Ref 8 63 
JWH-080 Butyl H Methoxy H Ref 8 7.6 
JWH-081 Pentyl H Methoxy H Ref 1 1.2 
JWH-082 Hexyl H Methoxy H Ref 8 5.3 
JWH-094 Propyl H Methoxy H Ref 8 Low affinity for CB1 receptor 476 
JWH-096 Butyl H Methoxy H Ref 8  34 
JWH-098 Pentyl Methyl Methoxy H Ref 1 4.5 
JWH-116 Pentyl Ethyl H H Ref 1 52 
JWH-120 Propyl H Methyl H Ref 6  Low affinity for CB1 receptor >1000 
JWH-122 Pentyl H Methyl H Ref 1 0.69 
JWH-148 Propyl Methyl Methyl H Ref 6  Low affinity for CB1 receptor 123 
JWH-149 Pentyl Methyl Methyl H Ref 1 5.0 
JWH-180 Propyl H Propyl H Ref 6 26 
JWH-181 Pentyl Methyl Propyl H Ref 6 1.3 
JWH-182 Pentyl H Propyl H Ref 6 0.65 
JWH-189 Propyl Methyl Propyl H Ref 6 52 
JWH-193 MPE H Methyl H Ref 1 6 
JWH-198 MPE H Methoxy H Ref 1 10 
JWH-200 MPE H H H Ref 1 42 
JWH-210 Pentyl H Ethyl H Ref 6 0.46 
JWH-211 Propyl Methyl Methyl H Ref 6 70 
JWH-212 Propyl H Ethyl H Ref 6 33 
JWH-213 Pentyl Methyl Ethyl H Ref 6 1.5 
JWH-234 Pentyl H H Ethyl Ref 6 8.4 
JWH-235 Propyl H H Ethyl Ref 6  Low affinity for CB1 receptor 338 
JWH-236 Propyl Methyl H Ethyl Ref 6  Low affinity for CB1 receptor >1000 
JWH-239 Propyl H Butyl H Ref 6  Low affinity for CB1 receptor 342 
JWH-240 Pentyl H Butyl H Ref 6 14 
JWH-241 Propyl Methyl Butyl H Ref 6  Low affinity for CB1 receptor 147 
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Group 1: Naphthoylindoles – contd. 
 
Substance R1 R2 R3 R4 Comments Ki (nM) 
JWH-242 Pentyl Methyl Butyl H Ref 6 42 
JWH-262 Pentyl Methyl H Ethyl Ref 6 28 
JWH? Butyl H H H Ref 7 8.9 
JWH? Pentyl H H H Ref 7 9 
JWH? Propyl Methyl H H Ref 7 Low affinity for CB1 receptor 164 
JWH? Ethyl Methyl H H Ref 7 Low affinity for CB1 receptor >1000 
JWH? Methyl Methyl H H Ref 7 Low affinity for CB1 receptor >1000 
JWH-386 Propyl H Br H Ref 8 Low affinity for CB1 receptor 161 
JWH-387 Pentyl H Br H Ref 8 1.2 
JWH-394 Pentyl Methyl Br H Ref 8 2.8 
JWH-395 Propyl Methyl Br H Ref 8 Low affinity for CB1 receptor 372 
JWH-397 Pentyl Methyl Cl H Ref 8 8.9 
JWH-398 Pentyl H Cl H Ref 8 2.3 
JWH-399 Propyl Methyl Cl H Ref 8 Low affinity for CB1 receptor 187 
JWH-400 Propyl H Cl H Ref 8 93 
JWH-412 Pentyl H F H Ref 8 7.2 
JWH-413 Pentyl Methyl F H Ref 8 14 
JWH-414 Propyl H F H Ref 8 Low affinity for CB1 receptor 240 
JWH-415 Propyl Methyl F H Ref 8 Low affinity for CB1 receptor 530 
Not named 2-Pentenyl Methyl H H Ref 7 Low affinity for CB1 receptor 340 
Not named 4-Pentenyl Methyl H H Ref 7 38 
Not named Allyl Methyl H H Ref 7 Low affinity for CB1 receptor >1000 
Not named 2-Pentenyl H H H Ref 7  58 
Not named 4-Pentenyl H H H Ref 7  43 
Not named 2-Phenylethyl Methyl H H Ref 7 Low affinity for CB1 receptor >1000 
Not named Cyclohexylethyl Methyl H H Ref 7 46 
Not named Cyclopropylmethyl Methyl H H Ref 7 Low affinity for CB1 receptor 140 
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Table 2.  Group 2: Naphthylmethylindoles
N
R1
R2
R3
 
 
Substance R1 R2 R3 Comments Ki (nM) 
JWH-175 Pentyl H H Ref 1 22 
JWH-184 Pentyl H Methyl Ref 1 23 
JWH-185 Pentyl H Methoxy Ref 1 17 
JWH-192 MPE H Methyl Ref 1 41 
JWH-194 Pentyl Methyl Methyl Ref 1  Low affinity for CB1 receptor 127 
JWH-195 MPE H H Ref 1  Low affinity for CB1 receptor 113 
JWH-196 Pentyl Methyl H Ref 1  Low affinity for CB1 receptor 151 
JWH-197 Pentyl Methyl Methoxy Ref 1  Low affinity for CB1 receptor 323 
JWH-199 MPE H Methoxy Ref 1 20 
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Table 3. Group 3: Naphthoylpyrroles R1
R2
N
O
 
 
Substance R1 R2 Comments Ki (nM) 
Unnamed? Methyl H Ref 7 Low affinity for CB1 receptor >1000 
Unnamed? Ethyl H Ref 7 Low affinity for CB1 receptor >1000 
Unnamed? Propyl H Ref 7 Low affinity for CB1 receptor >1000 
Unnamed? Butyl H Ref 7 Low affinity for CB1 receptor 666 
Unnamed? Hexyl H Ref 7 Low affinity for CB1 receptor 399 
Unnamed? Heptyl H Ref 7 Low affinity for CB1 receptor 309 
JWH-030 Pentyl H Ref 7 87 
JWH-145 Pentyl Phenyl Ref 8 14 
JWH-146 Heptyl Phenyl Ref 8 21 
JWH-147 Hexyl Phenyl Ref 8 11 
JWH-150 Butyl Phenyl Ref 8 60 
JWH-156 Propyl Phenyl Ref 8 Low affinity for CB1 receptor 404 
JWH-243 Pentyl 4-Methoxyphenyl Ref 8 Low affinity for CB1 receptor 285 
JWH-244 Pentyl 4-Methylphenyl Ref 8 Low affinity for CB1 receptor 130 
JWH-245 Pentyl 4-Chlorophenyl Ref 8 Low affinity for CB1 receptor 276 
JWH-246 Pentyl 3-Chlorophenyl Ref 8 70 
JWH-292 Pentyl 2-Methoxyphenyl Ref 8 29 
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Group 3: Naphthoylpyrroles  - contd. 
 
Substance R1 R2 Comments Ki (nM) 
JWH-293 Pentyl 3-Nitrophenyl Ref 8 Low affinity for CB1 receptor 100 
JWH-307 Pentyl 2-Fluorophenyl Ref 8 7.7 
JWH-308 Pentyl 4-Fluorophenyl Ref 8 41 
JWH-346 Pentyl 3-Methylphenyl Ref 8 67 
JWH-348 Pentyl 4-Trifluoromethylphenyl Ref 8 Low affinity for CB1 receptor 218 
JWH-363 Pentyl 3-Trifluoromethylphenyl Ref 8 Low affinity for CB1 receptor 245 
JWH-364 Pentyl 4-Ethylphenyl Ref 8 34 
JWH-365 Pentyl 2-Ethylphenyl Ref 8 17 
JWH-367 Pentyl 3-Methoxyphenyl Ref 8 53 
JWH-368 Pentyl 3-Fluorophenyl Ref 8 16 
JWH-369 Pentyl 2-Chlorophenyl Ref 8 7.9 
JWH-370 Pentyl 2-Methylphenyl Ref 8 5.6 
JWH-371 Pentyl 4-Butylphenyl Ref 8 42 
JWH-373 Pentyl 2-Butylphenyl Ref 8 60 
JWH-392 Pentyl 2-Trifluoromethylphenyl Ref 8 77 
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Table 4. Group 4: Naphthylmethylindenes R1
R2
 
 
Substance R1 R2 Comments Ki (nM) 
JWH-176 Pentyl H Ref 1 26 
Compound #7 MPE H Ref 1 2.7 
Compound #8 MPE Methyl Ref 1 2.9 
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Table 5. Group 5: Phenylacetylindoles   
N
O
R1
R2
C5H11  
 
Substance R1 R2 Comments Ki (nM) 
JWH-167 H Phenyl Ref 8 64 
JWH-201 H 4-Methoxyphenyl Ref 8 Low affinity for CB1 receptor >1000 
JWH-202 Methyl 4-Methoxyphenyl Ref 8 Low affinity for CB1 receptor >1000 
JWH-203 H 2-Chlorophenyl Ref 8 8.0 
JWH-204 Methyl 2-Chlorophenyl Ref 8 13 
JWH-205 Methyl Phenyl Ref 8 Low affinity for CB1 receptor 124 
JWH-206 H 4-Chlorophenyl Ref 8 Low affinity for CB1 receptor 389 
JWH-207 Methyl 4-Chlorophenyl Ref 8 Low affinity for CB1 receptor >1000 
JWH-208 H 4-Methylphenyl Ref 8 Low affinity for CB1 receptor 179 
JWH-209 Methyl 4-Methylphenyl Ref 8 Low affinity for CB1 receptor 746 
JWH-237 H 3-Chlorophenyl Ref 8 38 
JWH-248 H 4-Bromophenyl Ref 8 Low affinity for CB1 receptor >1000 
JWH-249 H 2-Bromophenyl Ref 8 8.4 
JWH-250 H 2-Methoxyphenyl Ref 8 11 
JWH-251 H 2-Methylphenyl Ref 8 29 
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Group 5: Phenylacetylindoles – contd.  
 
Substance R1 R2 Comments Ki (nM) 
JWH-252 Methyl 2-Methylphenyl Ref 8 23 
JWH-253 Methyl 3-Methoxyphenyl Ref 8 62 
JWH-302 H 3-Methoxyphenyl Ref 8 17 
JWH-303 Methyl 3-Chlorophenyl Ref 8 Low affinity for CB1 receptor 117 
JWH-304 Methyl 4-Bromophenyl Ref 8 Low affinity for CB1 receptor >1000 
JWH-305 Methyl 2-Bromophenyl Ref 8 15 
JWH-306 Methyl 2-Methoxyphenyl Ref 8 25 
JWH-311 H 2-Fluorophenyl Ref 8 23 
JWH-312 H 3-Fluorophenyl Ref 8 72 
JWH-313 H 4-Fluorophenyl Ref 8 Low affinity for CB1 receptor 422 
JWH-314 Methyl 2-Fluorophenyl Ref 8 39 
JWH-315 Methyl 3-Fluorophenyl Ref 8 Low affinity for CB1 receptor 430 
JWH-316 Methyl 4-Fluorophenyl Ref 8 Low affinity for CB1 receptor >1000 
 
ACMD report on the major cannabinoid agonists 
 24 
 
Table 6. Group 6: Cyclohexylphenols
OH
OH
R1R2  
 
Substance R1 R2 Comments Ki (nM) 
CP-55,940 1,1-Dimethylheptyl Hydroxypropyl Ref 1. (aka Analog XIV in Ref 11) 0.35 (Ref 8) 
CP-47,497 1,1-Dimethylheptyl H Ref 3. Controlled in D, A and F (aka Analog VI in Ref 
11) 
9.54 
Analog VII 1,1-Dimethyloctyl H Ref 3. Controlled in D, A and F (Homologue #1) 4.7 (Ref 12) 
Analog V 1,1-Dimethylhexyl H Controlled in D, A and F (Homologue #2) 126 (Ref 12) 
Analog VIII 1,1-Dimethylnonyl H Controlled in D, A and F (Homologue #3) 28.5 (Ref 12) 
Analog I 1,1-Dimethylethyl H Low affinity for CB1 receptor >1000 (Ref 12) 
Analog II 1,1-Dimethylpropyl H Low affinity for CB1 receptor >1000 (Ref 12) 
Analog III 1,1-Dimethylbutyl H Low affinity for CB1 receptor >1000 (Ref 12) 
Analog IV 1,1-Dimethylpentyl H Low affinity for CB1 receptor 735 (Ref 12) 
Analog IX 1,1-Dimethyldecyl H Low affinity for CB1 receptor 163 (Ref 12) 
Analog X 1,1-Dimethylundecyl H Low affinity for CB1 receptor 381 (Ref 12) 
Analog XI 1,1-Dimethylheptyl Methyl The C1-α-OH isomer of Analog XII 6.2 (Ref 12) 
Analog XII 1,1-Dimethylheptyl Methyl  7.7 (Ref 12) 
Analog XIII H Hydroxypropyl Low affinity for CB1 receptor >1000 (Ref 12) 
Analog XV 1,1-Dimethylheptyl Hydroxypropyl aka CP-56,667 62 (Ref 12) 
Analog XVI 1,1-Dimethylheptyl Hydroxybutyl  1.6 (Ref 12) 
Note: Analog numbers follow Table 1 in Ref 11. 
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Table 7. Group 7: Classical cannabinoids (Dibenzopyrans)
O
OH
R1
R2
A
8
9
10
 
 
Substance R1 R2 Comments Ki (nM) 
Δ9-THC Pentyl Methyl Phytocannabinoid. Unsaturation at C9-C10. Class B controlled. 10.2 (Ref 8) 
Δ8-THC Pentyl Methyl Phytocannabinoid. Unsaturation at C8-C9. Class B controlled. 16.5 (Ref 8) 
Nabilone 1,1-Dimethylheptyl Keto (=O) Ring A is saturated. Active component of Cesamet® 1.84 (Ref 9) 
HU-210 1,1-Dimethylheptyl Hydroxymethyl Unsaturation at C8-C9.  Controlled in F. 0.06 (Ref 4) 
HU-211 1,1-Dimethylheptyl Hydroxymethyl Unsaturation at C8-C9. Low affinity for CB1 receptor >100? (Ref 
4) 
unnamed 1,1-Cyclopropylheptyl Methyl Unsaturation at C8-C9. Class B controlled. 0.44 (Ref 9) 
unnamed 1,1-Dimethylcyclohexyl Methyl Unsaturation at C8-C9. Class B controlled. ? (Ref 9) 
unnamed 1,2-Dimethylheptyl Methyl Unsaturation at C8-C9. Class B controlled. <1.0 (Ref 10) 
unnamed 1,1-Dimethylheptyl Methyl Unsaturation at C8-C9. Class B controlled. <1.0 (Ref 10) 
Note: HU-211 is the 6aS,10aS enantiomer of HU-210, which is itself 6aR,10aR (Ref 4). 
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Annex B. Letter to Home Secretary re: ACMD concerns 
ACMD 
Advisory Council on the Misuse of Drugs 
Chair: Professor David Nutt 
Secretary: Will Reynolds 
 
3rd Floor (SW), Seacole Building 
2 Marsham Street 
London  
SW1P 4DF 
Tel: 020 7035 0454  
ACMD@homeoffice.gsi.gov.uk 
Rt Hon Jacqui Smith 
2 Marsham Street 
London  
SW1P 4DF 
8th April 2009 
 
Dear Home Secretary,  
 
I outlined in my letter of 31st March 2009 that I would write to you with initial 
advice regarding the drug ‘Spice’. The ACMD has received presentations on 
‘Spice’ from a member associated with the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) and has discussed the subject at some 
length at its recent technical committee meeting. 
 
Such is the concern regarding ‘Spice’ in the ACMD that I consider it timely to 
raise the issue with you now, while the Council is still developing its formal 
advice to you, which I hope to have completed by the end of May.  
 
‘Spice’ is a plant based smoking mix that does not contain tobacco. It is 
marketed as a herbal product almost exclusively on the internet. Products 
analysed in German samples have been found to contain synthetic 
cannabinoids that are believed to be of a higher potency than 
tetrahydrocannabinol (THC): the active principle in cannabis. Their detailed 
pharmacology is, as yet, unknown due, in part, to the large number of 
potential cannabinoids that can be synthesised. However, the ACMD’s 
chemists and pharmacologists can make some inferences based on the 
chemistry of the drugs identified to date and it is very likely that these 
synthetic cannabinoids will produce all the harmful effects that are associated 
with THC. 
 
The MHRA has written to three UK suppliers (October 2008) informing them 
that ‘Spice Gold’ is a medicinal product. All three companies have decided to 
cease sale and supply. However, we believe that this action has had little no 
effect on the supply of “Spice” in the UK either through internet or retail sales. 
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Currently, Austria, Germany and France in the EU have controlled those 
synthetic cannabinoids identified in Spice and an approximately similar 
number of other Member States have legislation pending.  
 
Presently, only a small number of synthetic cannabinoids have been identified 
in ‘Spice’. However, the potential range presents some challenges to ensure 
that any legislative changes are not easily subverted by manufacturers (which 
appear mainly to be based in China) changing the compounds they add. This 
concern is supported by recent experience in Germany that suggests that 
should one of the cannabinoids be controlled, manufacturers move to adding 
a chemically different, yet functionally similar, synthetic cannabinoid in the 
‘Spice’ mix. Due to the number of variations, it is highly likely that specific 
legislation would always run some way behind the availability of a legal mix on 
the street. Therefore, the ACMD is considering how best to use generic 
legislation to control the cannabinoids that are, or could in the future, be used 
in ‘Spice’, without impacting on any legitimate use of these or related 
substances. 
 
Although the synthetic cannabinoids fall within the definition of ‘new 
psychoactive substances’ as defined by EU Council Decision 2005/387/JHA, it 
is considered unlikely that the EMCDDA and Europol could carry out a risk 
assessment on more than a few representative members of the group. 
 
We aim to provide you with advice on classification, potential generic 
legislation and other recommendations in the minimum time necessary to 
complete our considerations. I have requested the ACMD Secretariat to 
regularly update your policy officials so that you are kept informed of our 
progress on this important matter.   
 
The example of ‘Spice’ has prompted the ACMD to consider the potential 
benefits of an expedited (but temporary) legislative procedure for harmful 
drugs that quickly become available on the market. The ACMD is concerned 
that at present the necessary processes to progress from an alert of a harmful 
drug through to legislation under the Misuse of Drugs Act 1971 takes some 
considerable time, usually years. During this period there is potential time for 
markets of a drug to become established and for harm to be caused. Such a 
measure may be particularly timely given the potential increase in synthetic 
drugs becoming available in the next few years. Such temporary control 
measures are already in use in the USA and Germany. 
 
Should you wish for further information on these matters I would welcome the 
opportunity to discuss them with you or your officials.  
 
Yours sincerely, 
 
 
Professor David Nutt FMed Sci 
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Annex C. Members of the Advisory Council on the Misuse of 
Drugs 
 
Member Sector 
Professor David Nutt 
(FMedSci), Chair 
 
Professor of Neuropsychopharmacology 
Imperial College London 
 
Dr Dima Abdulrahim Briefings Manager, National Treatment Agency 
 
Lord Victor Adebowale Chief Executive, Turning Point   
 
Mr Martin Barnes Chief Executive, DrugScope 
 
Dr Margaret Birtwistle Specialist General Practitioner, Senior Tutor – 
Education and Training Unit, St George’s 
Hospital and Forensic Medical Examiner  
 
Commander Simon Bray Commander, Metropolitan Police 
 
Dr Simon Campbell (CBE) Formerly Head of Worldwide Discovery, Pfizer 
 
Mr Eric Carlin 
 
Chief Executive, Mentor UK 
Ms Carmel Clancy Principal Lecturer in Mental Health and 
Addictions, Middlesex University  
 
Professor Ilana Crome Professor of Addiction Psychiatry, Keele 
University 
 
Ms Robyn Doran Mental Health Nurse and Director of Operations, 
North-West London Mental Health Trust 
 
Mr Patrick Hargreaves Adviser for Drugs and Alcohol, Durham County 
Council, Children and Young People's Services 
 
Ms Caroline Healy National Adviser for the commissioning of 
mental health services for children in secure 
settings, Department of Health 
 
Dr Matthew Hickman  Reader in Public Health and Epidemiology, 
Department of Social Medicine, University of  
Bristol 
  
Professor Leslie Iversen 
(FRS) 
Professor of Pharmacology, Oxford University 
 
 
Dr Leslie King Adviser to the Department of Health and the 
European Monitoring Centre for Drugs and Drug 
Addiction  
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Mr David Liddell 
 
Director, Scottish Drugs Forum 
Dr John Marsden Reader in psychology, Institute of Psychiatry 
(Adviser to the World Health Organisation and 
United Nations) 
 
Mr Peter Martin (CBE) 
 
Independent Consultant in Substance Misuse 
 
Dr Fiona Measham Senior Lecturer in Criminology, Lancaster 
University 
 
Ms Anita Nolan 
 
Consultant in oral medicince, Dundee Dental 
Hospital and School 
 
Mr Trevor Pearce Director of Enforcement, Serious Organised 
Crime Agency 
 
District Judge Justin 
Phillips 
 
District Judge, Drugs Court London 
Mr Richard Phillips 
 
Independent consultant, Phoenix Futures 
Dr Ian Ragan 
 
Pharmaceutical industry consultant (Head of 
European Scientific Affairs at Eli Lilly, Executive 
Director of the European Brain Council) 
  
DCC Howard Roberts Deputy Chief Constable, Nottinghamshire Police 
 
Dr Mary Rowlands Consultant psychiatrist in substance misuse, 
Exeter 
 
Dr Polly Taylor Veterinary Surgeon, Cambridgeshire 
 
Ms Monique Tomlinson Freelance Consultant in Drugs Misuse 
 
Mrs Marion Walker 
 
Clinical Director, Substance Misuse Service, 
Berkshire Healthcare NHS Trust 
 
Mr Arthur Wing Assistant Chief Officer – Sussex Probation Area 
 
 
 
 
 
